Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Dementia l: Introduction01:22

Dementia l: Introduction

35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antisense Oligonucleotide Tofersen Distribution in the Central Nervous System of SOD1-ALS Autopsy Tissue Donors.

JAMA neurology·2026
Same author

Characterisation of Posterior Predominant Amyloid PET Binding Across Multiple Cohorts.

bioRxiv : the preprint server for biology·2026
Same author

Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers.

JAMA neurology·2026
Same author

Features predicting data exclusion in imaging studies of Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Contributions of the Alzheimer's Disease Neuroimaging Initiative to advancing AD research: a targeted review of recent publications.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer's disease.

Acta neuropathologica·2026

Related Experiment Video

Updated: May 1, 2026

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.8K

Tracking the earliest pathologic changes in Alzheimer disease.

Susan M Landau1, Matthew P Frosch

  • 1From the Helen Wills Neuroscience Institute (S.M.L.), University of California and Lawrence Berkeley National Laboratory; and the Mass General Institute for Neurodegenerative Disease and C. S. Kubik Laboratory for Neuropathology (M.P.F.), Massachusetts General Hospital, Harvard Medical School, Charlestown.

Neurology
|April 8, 2014
PubMed
Summary
This summary is machine-generated.

Researchers are investigating the sequence of Alzheimer disease (AD) pathology before cognitive decline. Understanding the timing of amyloid and tau accumulation is key to unraveling AD pathogenesis.

More Related Videos

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
08:25

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

2.4K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.2K

Related Experiment Videos

Last Updated: May 1, 2026

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.8K
Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
08:25

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

2.4K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.2K

Area of Science:

  • Neuroscience
  • Pathology
  • Biomarker Research

Background:

  • Alzheimer disease (AD) research faces challenges in defining preclinical pathologic events.
  • The precise sequence of amyloid deposition and tau-mediated neurodegeneration in early AD is debated.
  • Studies integrate genetic, neuroimaging, fluid biomarker, animal, and autopsy data to elucidate AD progression.

Discussion:

  • Investigating the temporal relationship between amyloid plaques and neurofibrillary tangles is crucial.
  • Understanding these early changes may reveal therapeutic targets before significant neurodegeneration occurs.
  • The interplay between genetic predisposition and environmental factors in AD onset requires further exploration.

Key Insights:

  • The order of appearance of AD hallmarks (amyloid and tau) is a critical area of ongoing research.
  • Preclinical AD research aims to identify diagnostic and therapeutic windows.
  • Multimodal research approaches are essential for a comprehensive understanding of AD pathophysiology.

Outlook:

  • Future research will focus on refining the timeline of AD pathologic events.
  • Developing interventions targeting early-stage AD pathology is a primary goal.
  • Continued integration of diverse research methodologies will advance AD knowledge.